

Regrets:

MINUTES

CITY OF GREATER SUDBURY DRUG STRATEGY EXECUTIVE COMMITTEE DATE: APRIL 4, 2024 TIME: 11 A.M. TO 12:30 P.M. MICROSOFT TEAMS MEETING



Co-Chairs: Mustafa Hirji, Acting Medical Officer of Health and Chief Executive Officer, Public Health

Sudbury & Districts

Paul Pedersen, Chief of Police, Greater Sudbury Police Service

Present: City of Greater Sudbury (CGS):

Steve Jacques, General Manager, Community Development

Greater Sudbury Police Service (GSPS):

Paul Pedersen, Chief of Police

Natalie Hiltz, Deputy Chief of Operation

Daniel Despatie, Inspector, Integrated Operations

Public Health Sudbury & Districts (PHSD):

Mustafa Hirji, Acting Medical Officer of Health and Chief Executive Officer

Sherry Price, Program Manager, Mental Health and Substance Use

Stacey Gilbeau, Director, Health Promotion and Vaccine Preventable Diseases Tyler Campbell, Director, Children and Social Services, City of Greater Sudbury

Recorder: Manon Tessier, Public Health Sudbury & Districts

#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
1.0	Call TO ORDER/ROLL CALL	Dr. Hirji called the meeting to order at 11:05 a.m.	
2.0	WELCOME AND INTRODUCTIONS	Everyone was welcomed and introduced themselves.	
3.0	TERRITORIAL ACKNOWLEDGEMENT	S. Gilbeau acknowledged the ancestral Indigenous territory upon which this meeting was occurring.	
4.0	REVIEW AND APPROVAL OF AGENDA	The agenda was reviewed and approved.	
5.0	REVIEW AND APPROVAL OF MINUTES – May 30, 2023	The minutes from the previous meetings were approved as submitted.	
6.0	NEW BUSINESS		
6.1	Community Drug Strategy committee structure survey results	To inform next steps and help shape the new Community Drug Strategy (CDS) structure, Public Health Sudbury & Districts sought input (via the dissemination of a voluntary survey) from a vast network of community stakeholders including: • Summit participants. • Summit invitees. • Current members of the CDS and its committees/pillars. • Persons with Lived and Living Experience and Indigenous representatives.	





#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
		The survey findings helped inform the recommendations for the proposed CDS structure and membership. The majority of respondents supported the revitalization/restructuring of the CDS being organized around the below illustrated three streams (areas of focus/values) and four overarching (cross cutting) priorities.	
6.2	Recommendations for the restructuring of the Community Drug Strategy	Recommendations at it relates to the new CDS structure included: • Aligning operations with the three streams of the Summit: • Health promotion • Substance use care • Wrap-around supports • Embedding the cross-cutting priorities identified at the Summit throughout the strategy: • Structural stigma • System equity and elimination of barriers • Funding • Collaboration • Introducing additional sub-groups/ working groups, as needed, once the streams are formed, as issues or projects arise.	





#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
		 Formalizing the connection of the CDS to the Drug Strategy Network of Ontario via Terms of Reference. Exploring a formal connection to other community structure(s) (i.e., Community Safety and Well-Being) to ensure efforts are aligned, linked-up, and accountable. An overview of the proposed committee structure, accountability and reporting was provided. The CDS Executive Committee will provide oversight to the strategy. The CDS Steering Committee will be accountable to the CDS Executive Committee and be responsible for: Providing strategic direction, setting goals, defining objectives and ensuring alignment of work with the overall mission. Making key decisions and recommendations to the Executive Committee. Identifying potential risks and developing mitigation strategies. Developing an evaluation framework to monitor progress of the CDS and of the Summit recommendations. The three Health promotion, Substance use care and Wrap-around supports subcommittees representing the Summit streams will be accountable to the CDS Steering Committee and responsible for: Developing and implementing the workplan. Ensuring that the Summit priorities and general CDS initiatives are moving forward. 	





# Item Description of Outcome	Individual Responsible for Further Action and Deadline
It was noted that the above recommended structur will help ensure alignment of CDS operations with the current needs of the community while simultaneously providing oversight for the advancement of the Summit priorities in the presence of an ongoing toxic drug crisis. **Membership Recommendations** It was noted that the following proposed membership recommendations were aligned and guided by the federal government's Canadian Drugs and Substances Strategy (October 30, 2023) which aims to improve the health and safety of all Canadians by minimizing substance use related harms. * Honouring and elevating the voices and perspectives of People With Lived and Living Experience at the level of the Steering Committee. * Valuing and ensuring the inclusion of the voices of equity deserving groups across the lifespan (i.e., Indigenous, BIPOC (black, indigenous, and other people of color), newcomers, Francophone, youth, etc.) at the level of the Steering Committee. * Stream co-chairs maintaining membership with the Steering Committee. * Stream co-chairs leading the recruitment of stream members. * Developing membership parameters to foster balance amid the sectors.	





#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
		Membership parameters for the CDS Steering Committee include: Two Steering Committee Co-chairs Two representatives from the health promotion stream Two representatives from the wrap-around supports stream Two representatives from substance use care stream One recorder Representatives of PWLLE (number to be determined) Indigenous Peoples Indigenous community representatives (number to be determined) Representatives from equity deserving populations (number to be determined) Committee Structure Endorsement A discussion took place and Executive Committee members endorsed the new CDS committee structure recommendations, which will: align with the Summit's three streams, moving away from the four-pillar model. formalize the connection to the Drug Strategy Network of Ontario. explore partnerships with other community structures to ensure aligned and accountable efforts.	
6.3	Discussion and decisions on new Community Drug Strategy committee structure	CDS Executive Committee Membership An overview of the proposed membership was presented and it was noted that additional discussion was needed to identify the key	
		organizations to co-chair the Executive Committee, to determine the optimal number of committee	





seats and to identify the agencies essential for the success of the CDS Executive Committee. Co-chair Identification and Selection Co-chairs are essential for steering the direction of the Executive Committee and Community Drug Strategy and for providing diverse perspectives and leadership necessary for balanced decision-making. Considerations for co-chair selection will include expertise related to the toxic drug crisis, commitment to the CDS vision, mission, and objectives, and decision-making ability. Several agencies identified in the CDS survey as top leaders for the CDS (i.e., Public Health Sudbury & Districts; Health Sciences North; City of Greater Sudbury; Réseau Access Network) will be approached. Outreach will clarify roles, responsibilities, and time commitments for these potential agencies and individuals. Number of Seats It was recommended and agreed that a defined maximum number of seats be established to ensure efficiency and effectiveness, balancing a manageable committee size with the need for diverse perspectives and quorum for decision-making. The recommended and preferred number of seats on the committee was under 10. Additionally, it was agreed that outreach to	#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
potential agencies includes clear expectations regarding their roles, responsibilities, and time commitments. Agency Identification and Selection Key considerations for agency selection will include:			Success of the CDS Executive Committee. Co-chair Identification and Selection Co-chairs are essential for steering the direction of the Executive Committee and Community Drug Strategy and for providing diverse perspectives and leadership necessary for balanced decision-making. Considerations for co-chair selection will include expertise related to the toxic drug crisis, commitment to the CDS vision, mission, and objectives, and decision-making ability. Several agencies identified in the CDS survey as top leaders for the CDS (i.e., Public Health Sudbury & Districts; Health Sciences North; City of Greater Sudbury; Réseau Access Network) will be approached. Outreach will clarify roles, responsibilities, and time commitments for these potential agencies and individuals. Number of Seats It was recommended and agreed that a defined maximum number of seats be established to ensure efficiency and effectiveness, balancing a manageable committee size with the need for diverse perspectives and quorum for decision-making. The recommended and preferred number of seats on the committee was under 10. Additionally, it was agreed that outreach to potential agencies includes clear expectations regarding their roles, responsibilities, and time commitments. Agency Identification and Selection	





#	Item	 Description of Outcome Relevance of agency's work to committee goals. Willingness and capacity to actively participate/attend meetings. Diversity in agency size, scope. Representation from PWLLE, Indigenous, equity deserving groups 	Individual Responsible for Further Action and Deadline
6.4	Next Steps	 CDS Steering Committee Membership Following a discussion, the Executive Committee supported and endorsed the following recommendations: That the co-chairs of the Steering Committee mirror those of the Executive Committee, and outreach provide clarity in terms of their roles, responsibilities, and time commitments for these potential agencies and individuals. That the number of seats for individuals representing People With Lived and Living Experience, Indigenous and other equity deserving group perspectives be determined by the Steering Committee co-chairs. That the total maximum number of seats on the Steering Committee be less than 20. That the three stream co-chairs hold membership with the Steering Committee. The inaugural CDS Steering Committee meeting will 	
6.4	Next Steps	The inaugural CDS Steering Committee meeting will take place this month (April) to align the new structure based on today's meeting decisions. The purpose of this meeting will be to determine the stream co-chairs and process for membership. All Summit invitees, current CDS members, and individuals identified in the feedback survey will be invited to participate.	





#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
		It was recommended that the co-chairs remain in their roles temporarily until new co-chairs are elected, and this was met with unanimous support. The co-chairs of the three streams will meet in May to finalize the remaining seats for Indigenous representatives, People With Lived and Living Experience (PWLLE), and others. The goal is to implement the new structure by September 2024.	
7.0	CONSENT AGENDA		
7.1	Drug Warnings and Alerts	Since the last Executive Committee meeting, drug warnings of increase in suspected drug poisonings (overdoses) were issued on: • March 19, 2024 • March 4, 2024 • February 21, 2024 • November 17, 2023 • September 11 • June 16, 2023 A drug alert confirming the presence of flubromazolam was also issued on September 27, 2023.	
7.2	Drug Strategy Network of Ontario letter of support	Executive Committee members were informed that a request for a letter of support for supervised consumption services in Ontario was received from the Drug Strategy Network of Ontario.	
8.0	2024 MEETINGS	The Executive Committee normally meets four times per year, preferably during the first week of the month that it is scheduled and from 10:30 a.m. to 12 p.m., and/or at the call of the Chair. Meeting dates for 2024 will be established, followed by calendar invitations.	M. Tessier





#	ltem	Description of Outcome	Individual Responsible for Further Action and Deadline
9.0	ADJOURNMENT	The meeting was adjourned at 12:14 p.m.	